Lipoprotein(a): Aspects of pathophysiology, epidemiology and treatment;Lipoprotein(a): Aspekte der Pathophysiologie, Epidemiologie und Behandlung

Zeitschrift fur Kardiologie

Volumn 92, Issue SUPPL. 3, 2003, Pages 53-58

  Thomas, H P ^a   Steinhagen Thiessen, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apheresis; CHD; Lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A;

APHERESIS; CARDIOVASCULAR DISEASE; CORONARY RISK; DISULFIDE BOND; EPIDEMIOLOGICAL DATA; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; PATHOPHYSIOLOGY; REVIEW; STANDARDIZATION; THROMBOEMBOLISM;

EID: 0345871055     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D (1986) The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 62:249-257
2. Berg K (1963) A new serum type system in man: the Lp(a) system. Acta pathol Micobiol Sand 59:369-382
3. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, Schaefer EJ, Castelli WP (1996) Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 276:544-548
4. Cantin B, Gagnon F, Moorjani S, Després JP, Lamarche B, Lupien PJ, Dagenais GR (1998) Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec cardiovascular study. JACC 31:519-525
5. Carlson LA, Hamsten A, Asplund A (1989) Pronounced lowering of serum lipoprotein Lp(a) in hyperlipemic subjects treated with nicotinic acid. J Intern Med 226:271
6. Cremer P, Nagel D, Labrot B, Mann H, Müller-Berninger R, Elster H, Seidel D (1997) Ten-year follow-up results from the Goettingen risk, incidence and prevalence study (GRIPS) I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 129:221-230
7. Dahlen G, Berg K, Gillnas T, Ericson C (1975) Lp(a) lipoprotein/pre- beta1-lipoprotein in Swedish middle-aged males and in patients with coronary heart disease. Clin Genet 7:334-341
8. Daida H, Lee YJ, Yokoi H, Kanoh T, Ishiwata S, Kato K, Nishikawa H, Takatsu F, Kato H, Kutsumi Y, Yamada N, Noma A, Yamaguchi H and the low-density lipoprotein apheresis angioplasty restenosis trial (L-Art) group (1994) Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Am J Cardiol 73:1037-1040
9. Danesh J, Collins R, Peto R (2000) Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102:1082-1085
10. von Depka M, Nowak-Göttl U, Eisert R, Dieterich C, Barthels M, Scharrer I, Ganser A, Ehrenforth S (2000) Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96:3364-3368
11. Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu QT, Miller CG, Lawn RM, Scanu AM (1987) Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 84:3224-3228
12. von Eckardstein A, Schulte H, Cullen P, Assmann G (2001) Lipoprotein (a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 1(38):1584-1585
13. Genest J Jr, Jenner JL, McNamara JR, Ordovas JM, Silberman SR, Wilson PW, Schaefer EJ (1991) Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 67:1039-1045
14. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK (1991) Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 89:59-67
15. Holmer SR, Hengstenberg C, Kraft HG, Mayer B, Poll M, Kurzinger S, Fischer M, Lowel H, Klein G, Riegger GA, Schunkert H (2003) Association of polymorphisms of the apolipoprotein (a) gene with lipoprotein (a) levels and myocardial infarction. Circulation 107:696-701
16. Jovicic A, Ivanisevic V, Ivanovic I (1993) Lipoprotein(a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis 98:59-65
17. Kiortsis DN, Tzotzas T, Ciral P, Bruckert E, Bender I, Valsamides S, Turpin G (2001) Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program. Nutr. Metab Cardiovasc Dis 11: 153-151
18. Költringer P, Jürgens G (1985) A dominant role of lipoprotein (a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis 58:187-198
19. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB (1981) Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 38:51-61
20. Kronenberg F, Kronenberg M, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J (1999) Role of lipoprotein (a) and apolipoprotein(a) phenotype in atherogenesis. Results from the Bruneck study. Circulation 100:1154-1160
21. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10:1027-1036
22. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G (1996) Lipoprotein (a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol 16:1568-1572
23. Liberopoulos E, Pavlidis N, Elisaf M (2001) The effect of tamoxifen therapy on serum apolipoprotein A-1 level is modified by the apolipoprotein E phenotype. Clin Biochem 34:161
24. Mackinnon LT, Hubinger L, Lepre F (1997) Effects of physical activity and diet on lipoprotein (a). Med Sci Sports Exerc 29:1429-1436
25. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF (1989) A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 339:301-303
26. Miltiadous G, Tsimihodimos V, Bairaktari E, Elias M (2001) Lipoprotein(a) levels in patients with homozygous familial hypercholesteolaemia. Atherosclerosis 157:255-256
27. Nowak-Göttl U, Strater R, Heinecke A, Junker R, Koch HG, Schuierer G, von Eckardstein A (1999) Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 94:3678-3682
28. Pekelharing HL, Kleinveld HA, Duif PF, Bouma BN, van Rijn HJ (1996) Effect of lipoprotein (a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator. Thromb Haemost 75:497-502
29. Prior M, Arosio E, Ferrari M, Lucchese L, Guidi GC, Bosello O (1995) Lipoprotein (a) and general risk factors in patients with angiographically assessed peripheral arterial disease. Int Angiol 14:357-363
30. Ridker PM, Hennekens CH, Stampfer MJ (1993) A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA 270:2195-2199
31. Ridker PM, Stampfer MJ, Rifai N (2001). Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481-2485
32. Shinozaki K, Kambajyshi J, Kawasaki T, Uemura Y, Sakon M, Shiba E, Shibuya T, Nakamura T, Mori T (1996). The long-term effect of eicosapentaenoic acid on serum levels of lipoprotein(a) and lipids in patients with vascular disease. J Atheroscler Thromb 2:107-109
33. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB (2000) Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause. J Am Med Assoc 283:1845-1852
34. Steinhagen-Thiessen E, Borchelt M (1996) Morbidität, Medikation und Funktionalität im Alter. In: Baltes KU, Meyer PB (Hrsg) Die Berliner Altersstudie. Akademie Verlag, Berlin 151-184
35. Superko HR, Hecht HS (2001) Metabolic disorders contribute to subclinical coronary atherosclerosis in patients with coronary calcification. Am J Cardiol 88:260-264
36. Thiery J, Seidel D (1998) Safety and effectiveness of long-term LDL-apheresis in patients at high risk. Curr Opin Lipidol 9:521-526
37. Ullrich H, Lackner K, Schmitz G (1997) Lipoprotein (a)-apheresis in the secondary prevention of coronary heart disease. Transfus Sci 17:511-517
38. Utermann G (1999) Genetic architecture and evolution of the lipoprotein (a) trait. Curr Opin Lipidol 10: 133-141
39. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C (1987) Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80:458-465